Home     Site Map     Legal   
  News Archive
  Latest News

August 27, 2010 MBC Pharma, Inc. awarded an SBIR Phase II grant ($1,795,054) to investigate new compounds for prostate cancer (read more)
October 7, 2009 MBC Pharma, Inc. announces issuance of a key patent (read more)
October 27, 2008 MBC Pharma, Inc. awarded an SBIR Phase II grant ($758,000) to investigate new compounds for multiple myeloma (read more)
November 30, 2007 MBC Pharma secures $1.8M in private financing
June 29, 2007 MBC Pharma conducts a successful pre-IND meeting with FDA to validate development plan for MBC-11 for treatment of Cancer Induced Bone Diseases
June 6, 2007 MBC Pharma received $100,000 NIH SBIR grant "Novel bisphosphonates for prostate cancer therapy"
March, 2006 MBC Pharma presents latest results on vtamin B6 derivative of alendronate (MBC-31) on Eighth and Valedictory Workshop on Bisphosphonates, Davos, Switzerland, March 22-24, 2006
January, 2006 MBC Pharma newsletter
May 24, 2005 MBC Pharma awarded US Patent 6,896,781 B2
April 1, 2005 Mayo Clinic and MBC Pharma submit phase 2 STTR grant application to NIH entitled "Novel bisphosphonates for breast cancer therapy"


MBC Pharma, Inc.   12635 E. Montview Blvd., Suite 100  Aurora, CO 80045
Phone: 720-859-4041  Fax: 303-484-3532
Email: information@mbcpharma.com